Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANGIODYNAMICS INCANGO · Entity 5275 | SVP/GM, Global Vascular | July 12, 2019 | August 20, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANGIODYNAMICS INC
Report date July 12, 2019 · Filed August 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,883 |
Ending reported balance
After 2019-07-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-07-12 · Exercise / conversion · Acquired 15,600 · Balance 31,041 F1: This acquisition of 15,600 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on January 31, 2017. Row 2 · 2019-07-12 · Tax withholding · Disposed 5,158 · Balance 25,883 F2: The exempt disposition of 5,158 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on January 31, 2017. |
| Performance RightSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-07-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-12 · Exercise / conversion · Acquired 30,000 · Balance 0 F3: On January 31, 2017, the reporting person received a target grant of 30,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 15,600 shares of Common Stock were issued to the reporting person under this grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This acquisition of 15,600 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on January 31, 2017.
F2: The exempt disposition of 5,158 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on January 31, 2017.
F3: On January 31, 2017, the reporting person received a target grant of 30,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 15,600 shares of Common Stock were issued to the reporting person under this grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2019 Filed Aug 2, 2019 20:29 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 309 | $20.89 | $6,455.01 |
DisclosureSEC source: 0001567619-19-015720 · doc1.xml · nonDerivative · entry 1 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,441 F1 · shares: The exempt disposition of 309 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017. Read SEC document |
| July 18, 2019 Filed Jul 25, 2019 20:42 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 148 | $21.53 | $3,186.44 |
DisclosureSEC source: 0001567619-19-015199 · doc1.xml · nonDerivative · entry 2 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 F2 · shares: The exempt disposition of 148 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 18, 2019 Filed Jul 25, 2019 20:42 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 244 | $21.53 | $5,253.32 |
DisclosureSEC source: 0001567619-19-015199 · doc1.xml · nonDerivative · entry 1 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,898 F1 · shares: The exempt disposition of 244 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 02:00 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionPerformance Right · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017318 · doc1.xml · derivative · entry 3 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On January 31, 2017, the reporting person received a target grant of 30,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 15,600 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.exercise_date: On January 31, 2017, the reporting person received a target grant of 30,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 15,600 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.expiration_date: On January 31, 2017, the reporting person received a target grant of 30,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 15,600 shares of Common Stock were issued to the reporting person under this grant. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 02:00 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 5,158 | $21.68 | $111,825.44 |
DisclosureSEC source: 0001567619-19-017318 · doc1.xml · nonDerivative · entry 2 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,883 F2 · shares: The exempt disposition of 5,158 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on January 31, 2017. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 02:00 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionCommon Stock | 15,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017318 · doc1.xml · nonDerivative · entry 1 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This acquisition of 15,600 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on January 31, 2017. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 21:24 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 981 | $21.10 | $20,699.10 |
DisclosureSEC source: 0001567619-19-002168 · doc1.xml · nonDerivative · entry 1 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,142 F1 · shares: The exempt disposition of 981 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on January 31, 2017. Read SEC document |
| July 26, 2018 Filed Jul 27, 2018 23:55 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 308 | $21.88 | $6,739.04 |
DisclosureSEC source: 0001140361-18-033940 · doc1.xml · nonDerivative · entry 1 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,123 F1 · shares: The exempt disposition of 308 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017. Read SEC document |
| July 18, 2018 Filed Jul 21, 2018 01:43 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantPerformance Right · Derivative | 9,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033099 · doc1.xml · derivative · entry 3 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,496 Underlying: Common Stock · 9,496 shares Expires not disclosed F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited. F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited. F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 18, 2018 Filed Jul 21, 2018 01:43 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,126 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001140361-18-033099 · doc1.xml · derivative · entry 2 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,126 Underlying: Common Stock · 15,126 shares Expires 2028-07-18 F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 18, 2019, such that 25% of the options will vest on each of July 18, 2019, 2020, 2021 and 2022. Read SEC document |
| July 18, 2018 Filed Jul 21, 2018 01:43 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 4,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033099 · doc1.xml · nonDerivative · entry 1 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,431 F1 · shares: This acquisition of 4,748 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 4,748 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 18, 2019, such that 25% of the restricted stock units will vest on each of July 18, 2019, 2020, 2021 and 2022. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:12 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 1,056 | $17.41 | $18,384.96 |
DisclosureSEC source: 0001140361-18-004709 · doc1.xml · nonDerivative · entry 1 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,683 F1 · shares: The exempt disposition of 1,056 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on January 31, 2017. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 19:12 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantPerformance Right · Derivative | 7,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-029085 · doc1.xml · derivative · entry 3 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,477 Underlying: Common Stock · 7,477 shares Expires not disclosed F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited. F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited. F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 19:12 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,137 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0001140361-17-029085 · doc1.xml · derivative · entry 2 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,137 Underlying: Common Stock · 13,137 shares Expires 2027-07-26 F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 19:12 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 3,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-029085 · doc1.xml · nonDerivative · entry 1 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,739 F1 · shares: This acquisition of 3,739 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,739 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.